Trial Profile
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Chondrosarcoma; Ewing's sarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 07 Jun 2022 Results assessing association of gut microbial signatures and B cells and tertiary lymphoid structures for determining response in patient specimens from three randomized phase 2 trials (NCT02519322;NCT03158129; NCT02301039) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 25 Sep 2020 Status changed from active, no longer recruiting to completed.
- 03 Jan 2020 Results (n=86) assessing tumor regression following anti-PD-1 therapy published in the Clinical Cancer Research